Inalegwu Auchi, Phillips Sunny, Datir Rawlings, Chime Christopher, Ozumba Petronilla, Peters Samuel, Ogbanufe Obinna, Mensah Charles, Abimiku Alash'Le, Dakum Patrick, Ndembi Nicaise
Auchi Inalegwu, Sunny Phillips, Rawlings Datir, Christopher Chime, Petronilla Ozumba, Samuel Peters, Charles Mensah, Alash'Le Abimiku, Patrick Dakum, Nicaise Ndembi, Institute of Human Virology, Abuja 900246, Federal Capital Territory, Nigeria.
World J Virol. 2016 May 12;5(2):73-81. doi: 10.5501/wjv.v5.i2.73.
To study the impact of rejection at different levels of health care by retrospectively reviewing records of dried blood spot samples received at the molecular laboratory for human immunodeficiency virus (HIV) early infant diagnosis (EID) between January 2008 and December 2012.
The specimen rejection rate, reasons for rejection and the impact of rejection at different levels of health care was examined. The extracted data were cleaned and checked for consistency and then de-duplicated using the unique patient and clinic identifiers. The cleaned data were ciphered and exported to SPSS version 19 (SPSS 2010 IBM Corp, New York, United States) for statistical analyses.
Sample rejection rate of 2.4% (n = 786/32552) and repeat rate of 8.8% (n = 69/786) were established. The mean age of infants presenting for first HIV molecular test among accepted valid samples was 17.83 wk (95%CI: 17.65-18.01) vs 20.30 wk (95%CI: 16.53-24.06) for repeated samples. HIV infection rate was 9.8% vs 15.9% for accepted and repeated samples. Compared to tertiary healthcare clinics, secondary and primary clinics had two-fold and three-fold higher likelihood of sample rejection, respectively (P < 0.05). We observed a significant increase in sample rejection rate with increasing number of EID clinics (r = 0.893, P = 0.041). The major reasons for rejection were improper sample collection (26.3%), improper labeling (16.4%) and insufficient blood (14.8%).
Programs should monitor pre-analytical variables and incorporate continuous quality improvement interventions to reduce errors associated with sample rejection and improve patient retention.
通过回顾性分析2008年1月至2012年12月间分子实验室接收的用于人类免疫缺陷病毒(HIV)早期婴儿诊断(EID)的干血斑样本记录,研究不同医疗保健水平下样本拒收的影响。
检查样本拒收率、拒收原因以及不同医疗保健水平下拒收的影响。对提取的数据进行清理并检查一致性,然后使用唯一的患者和诊所标识符进行去重。清理后的数据进行加密并导出到SPSS 19版(SPSS 2010,IBM公司,美国纽约)进行统计分析。
确定样本拒收率为2.4%(n = 786/32552),重复率为8.8%(n = 69/786)。接受的有效样本中首次进行HIV分子检测的婴儿平均年龄为17.83周(95%可信区间:17.65 - 18.01),而重复样本的平均年龄为20.30周(95%可信区间:16.53 - 24.06)。接受样本和重复样本的HIV感染率分别为9.8%和15.9%。与三级医疗诊所相比,二级和一级诊所样本拒收的可能性分别高出两倍和三倍(P < 0.05)。我们观察到随着EID诊所数量的增加,样本拒收率显著上升(r = 0.893,P = 0.041)。拒收的主要原因是样本采集不当(26.3%)、标签标注不当(16.4%)和血量不足(14.8%)。
各项目应监测分析前变量,并纳入持续质量改进干预措施,以减少与样本拒收相关的误差并提高患者留存率。